Metastasis is responsible for more than 90% of the mortality observed among patients with breast cancer. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a novel member of the PEBP family and functions as an anti-apoptotic molecule. Here, we found that the metastatic MDA-MB-231 breast cancer cells expressed much higher levels of hPEBP4 than the nonmetastatic MCF-7 breast cancer cells and that the expression levels of hPEBP4 were positively correlated with the metastasis of clinical breast cancer. The hPEBP4 overexpression in the MDA-MB-231 cells significantly promoted cell invasion in vitro and increased the development of lymph node metastasis in vivo. Conversely, the silencing of hPEBP4 suppressed the cell-invasive ability both in vitro and in vivo. Further investigation showed that hPEBP4 promoted the expression or activity of the metastasisrelated proteinases MMP (matrix metalloproteinase) 2, MMP9 and MMP13. This hPEBP4-potentiated cell invasion and MMP expression is due to an increase in Akt activation. Knockdown of Akt restored hPEBP4-induced breast tumor metastasis in the hPEBP4-MDA-MB-231 xenograft mouse model. Moreover, we found that hPEBP4 functioned as a scaffolding molecule and enhanced the association of Akt with Src to promote Akt tyrosine phosphorylation, a prerequisite for the full activation of Akt, in a phosphatidylethanolamine-binding domain-dependent manner. Given the present information about human breast cancer, these functional data from cell culture and animal studies suggest that, in human breast cancer hPEBP4 is a novel and clinically relevant metastasis accelerator gene and may be a new diagnostic marker and therapeutic target for breast cancer metastasis. 
INTRODUCTION
Breast cancer is the most common malignant disease in women in both developed and developing countries. In breast cancer patients, metastasis at distant sites, rather than the primary tumor itself, is the main cause of death. 1 The metastasis of breast cancer is a multifactor, multistage and multistep biological process. The early diagnosis of breast cancer requires studies to identify molecular targets, and effective treatment discoveries require studies of the molecular mechanisms involved in primary tumor cell invasion and metastasis.
Because alterations in signaling pathways that regulate cell proliferation, apoptosis, migration, invasion, cell attachment, and angiogenesis are central to the metastasis of breast cancer, many studies have focused on the deregulation of the signaling pathways involved in the metastasis process. Activation of the PI3K/Akt pathway in breast cancer occurs at frequencies as high as 70%, and some studies have indicated that the level of active Akt is much higher in metastatic breast cancer cells than in nonmetastatic tumor cells. 2 Other important pathways involved in cancer metastasis are the mitogen-activated protein kinase and nuclear factor (NF)-kB pathways. Angiogenesis, adhesion, extravasation and degradation of the extracellular matrix are all associated with constitutive MAPK and NF-kB activation. [3] [4] [5] Thus, identifying the molecules involved in the deregulated signaling pathways and elucidating the underlying molecular mechanisms have helped to identify potentially effective treatments for breast cancer and may contribute to the early diagnosis of malignant breast cancer.
The human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a member of the evolutionarily conserved phosphatidylethanolamine-binding (PEB) protein family and has been identified by us as a novel anti-apoptotic protein. 6 hPEBP4 is preferentially expressed in several cancers, including breast cancer, prostate cancer, lung squamous cell carcinoma and ovarian cancer. [6] [7] [8] [9] hPEBP4 promotes cellular resistance to tumor necrosis factor-a/related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibiting the activation of the Jun N-terminal kinase (JNK) and v-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1)/MAPK/Erk kinase (MEK)/ extracellular signal-regulated kinase (ERK) 1/2 pathways. [6] [7] [8] [9] [10] Recent studies have found that the expression of hPEBP4 mRNA and protein in non-small cell lung cancer tissues of patients with lymph node metastasis was significantly higher than in patients without lymph node metastasis, similar to what is observed in patients with colorectal cancer. [11] [12] [13] Yu et al. 14 reported that the silencing of hPEBP4 inhibited cell proliferation and cell-invasive ability in the HCC827 non-small cell lung cancer cell line. In addition, we determined that mouse PEBP4 promoted the migration and invasion of mouse breast cancer 4T1 cells in vitro. 15 Taken together, these results suggest that hPEBP4 may promote cell invasion. However, whether hPEBP4 actually promotes metastasis and the exact mechanisms that underlie the effects of hPEBP4 remain unclear. In this study, we used the MDA-MB-231 model to illustrate the function of hPEBP4 in promoting breast cancer metastasis to lymph nodes and the underlying molecular mechanisms. Based on the positive correlation of hPEBP4 expression with breast cancer metastasis in clinical samples, hPEBP4 may serve as a new diagnostic marker and therapeutic target for breast cancer metastasis.
RESULTS
Increased hPEBP4 expression in the metastatic breast cancer and lymph node metastases To address the relationship between hPEBP4 expression and the metastasis of breast cancer, human tissue microarrays containing an additional 128 breast tissue samples, including 50 normal breast tissues, 56 primary tumors and 22 lymph node metastases, were used to detect the expression of hPEBP4 by immunohistochemistry. As shown in Figure 1 , the hPEBP4 expression level was highest for the lymph node metastases, lower for the matched primary breast cancer tissue and absent in the adjacent normal breast tissue. In agreement with our previous results, 7 hPEBP4 was detectable in a very high percentage of breast cancer tissue (92.9%) but only in a low percentage of normal breast tissue (18%, P ¼ 0.004; Table 1 ). In addition, all lymph node metastases expressed the hPEBP4 protein (22/22) . Moreover, 36.4% (8/22) of the lymph node metastases exhibited strong hPEBP4 staining, whereas only 12.5% of the primary breast cancers showed strong hPEBP4 staining (P ¼ 0.032; Table 1, Figure 1 ). Simultaneously, in the 32 tumors with lymph node metastasis, 22% (7/32) exhibited a strong hPEBP4 signal, whereas none of the remaining 24 tumors without metastasis exhibited a strong hPEBP4 signal (P ¼ 0.049; Table 1 ). These results revealed a positive correlation of hPEBP4 expression with lymph node metastasis in human breast cancer and suggest that hPEBP4 may be involved in the development and progression of breast cancer metastasis.
hPEBP4 promotes the invasion of breast cancer cells in vitro To determine whether hPEBP4 was involved in the regulation of breast cancer metastasis, the hPEBP4 expression pattern in the highly metastatic breast cancer MDA-MB-231 cells, the moderately metastatic breast cancer MDA-MB-468 and T47D cells and in the nonmetastatic breast cancer MCF-7 cells was examined. As shown in Supplementary Figure 1B , the MDA-MB-231, MDA-MB-468 and T47D cells express 10-fold, 4-fold and 4-fold more hPEBP4 mRNA, respectively, and approximately 5-fold, 2-fold and 2-fold more hPEBP4 protein, respectively, than the MCF-7 cells. We then modified the hPEBP4 expression in breast cancer cells by stably transfecting MDA-MB-231 cells with an hPEBP4 expression vector or an shPEBP4 plasmid. The western blot confirmed hPEBP4 overexpression or silencing in the MDA-MB-231 stable transfectants (Figure 2a ). There were no significant differences in proliferation in vitro between the mock vector-transfected and the hPEBP4-transfected cells or between the control vector (shNC)-transfected and the shPEBP4-transfected cells (Supplementary Figure 2A) . Furthermore, the migration and wound healing assays in vitro showed that hPEBP4 had no motility-promoting activity in MDA-MB-231 cells based on both hPEBP4 overexpression and hPEBP4 knockdown (Supplementary Figures 2B and C) . However, the invasion ability of the MDA-MB-231/hPEBP4-B cells was increased more than 3-fold compared with the MDA-MB-231/mock cells (P ¼ 0.0053; Figure 2b ). Conversely, decreasing the hPEBP4 expression led to a 3-4-fold reduction in the invasive properties of the breast cancer cells compared with the shNC control-transfected cells (P ¼ 0.0025; Figure 2c ), suggesting that hPEBP4 expression was positively associated with the invasiveness of the breast cancer cells. Similar results were obtained in another metastatic breast cancer cell line MDA-MB-468, as well as in the melanoma cell line MDA-MB-435S, the colorectal cancer cell line SW620 and the liver cancer cell line HEPG2 (Supplementary Figure 2D) . We next determined the changes in the expression of several metastatic genes. The overexpression of hPEBP4 dramatically promotes the expression of MMP2, MMP9 and MMP13 compared with the control cells at the mRNA level (Supplementary Figure 3A) . Conversely, the Figure 3B) . However, the expression levels of other genes were not affected. The protein levels of the epithelial-tomesenchymal transition markers and MMPs were examined using western blot, immunofluorescence and flow cytometry analysis to confirm the results of qPCR. Consistently, hPEBP4 promoted the expression of the MMP2, MMP9 and MMP13 proteins but had no effect on the other proteins ( Figure 2d , Supplementary Figures 3C  and D) . We also measured the enzymatic activities of the MMPs by hPEBP4 promotes the metastasis of breast cancer H Li et al gelatin zymography using conditioned medium. As shown in Figure 2e and Supplementary Figure 3E , gelatin zymography showed stronger lytic zones at the molecular masses corresponding to MMP2 and MMP9 in cells with elevated hPEBP4 expression. Simultaneously, the activities of MMP2 and MMP9 were dramatically decreased when hPEBP4 was knocked down. These data are consistent with the results observed in the cell invasion assays, indicating that hPEBP4 enhanced the expression or activities of MMP2, MMP9 and MMP13, and potentiated the invasion of breast cancer cells.
hPEBP4 facilitates breast cancer metastasis in a murine allograft model A key question was whether hPEBEP4 could promote metastatic behaviors in vivo. To examine this possibility, we designed lentiviruses carrying hPEBP4 cDNA or a vector expressing shPEBP4 to infect the MDA-MB-231-Luc-D3H2LN cells that had been engineered to stably express firefly luciferase, and we then implanted the cells into the mammary fat pads of mice to examine the effect of hPEBP4 on spontaneous lung metastasis. Figure 4D) . Interestingly, the rate of spontaneous lung metastasis was increased in animals carrying MDA-MB-231-Luc-D3H2LN tumors with hPEBP4 overexpression and was inhibited in animals carrying MDA-MB-231-Luc-D3H2LN tumors with the hPEBP4 knockdown, as measured by bioluminescence imaging to quantify the photon flux (Figures 3a and b) . The histological assessment of the lungs showed more tumor colonies in the hPEBP4 overexpression groups and fewer tumor colonies in the hPEBP4-silenced groups (Supplementary Figure 4E) , strongly suggesting that hPEBP4 increased spontaneous lung metastasis in vivo.
We also measured the ability of MDA-MB-231-Luc cells to enter the circulation at the early stage of tumor metastasis by analyzing the expression of human (tumor) and mouse (control) glyceraldehyde phosphate dehydrogenase transcripts in cells isolated from the blood. Quantitative RT-PCR showed that the overexpression of hPEBP4 apparently promoted tumor cell intravasation, whereas hPEBP4 downregulation suppressed tumor cell intravasation (Figures 3a and b). Invasion and intravasation are necessary early events in the metastatic cascade. We used lung seeding metastasis models by intravenous injection to examine whether hPEBP4 can also regulate late metastatic events, such as colonization and/or growth at a distant site. A significant increase in the lung metastasis of tumor cells was observed in mice injected with MDA-MB-231-Luc-D3H2LN cells overexpressing hPEBP4 compared with the mock group (Figure 3c ), whereas a significant decrease in the lung metastasis of tumor cells was recorded in animals injected with MDA-MB-231-Luc-D3H2LN cells with hPEBP4 knockdown (Figure 3d ). These observations were confirmed by histological staining (Supplementary Figure 4F) . Thus, all of the above experiments indicated that hPEBP4 enhanced the metastatic spread of MDA-MB-231-Luc-D3H2LN cells in vivo, thereby acting as a potential prometastatic gene. Figure 4a ). To determine whether enhanced Akt activation may be involved in the promoting effect of hPEBP4 on the invasion of MDA-MB-231 cells through Matrigel, we performed invasion experiments in the presence of 20 mM LY294002, a PI3K inhibitor. LY-294002 strongly inhibited the serum-mediated Akt activation (data not shown) and reversed the promoting effect of hPEBP4 on the breast cancer cell invasion and the expression of the MMPs (Figure 4b ). However, although the western blot most likely indicates a reduction of MMP protein expression, it was not possible to determine whether active MMP enzyme activity was changed by LY294002 treatment. At the same time, silencing of Akt1 not only restored the hPEBP4-induced breast cancer invasion in vitro, but also inhibited hPEBP4-mediated breast tumor metastasis in the hPEBP4-MDA-MB-231 xenograft mouse model (Supplementary Figures 5A and B) .
In contrast, knockdown of hPEBP4 suppressed Akt phosphorylation and enhanced serum-induced ERK1/2 activation; however, it still had no effect on the activation of the other signal pathways (Figure 4c ). We next explored whether the enhanced ERK1/2 activation contributed to the suppression of cell invasion induced by hPEBP4 interference. However, treatment with U0126, a MEK inhibitor, did not rescue either the impaired invasion or the decrease in MMP expression mediated by hPEBP4 interference (Figure 4d ). In addition, hPEBP4-silenced and control cells were transfected with a constitutively activated Akt (Myr-Akt) construct. 16 The ectopic expression of Myr-Akt not only increased the invasive ability of breast cancer cells and MMP expression but also reversed the inhibitory effect of hPEBP4 silencing on cell invasion and MMP expression (Figure 4e ). These data confirmed the importance of Akt activation but not ERK activation in the hPEBP4-mediated invasion in MDA-MB-231 cells. Collectively, hPEBP4 promoted breast cancer invasion by regulating the expression and activities of the MMPs, which required Akt activation.
hPEBP4 enhances the interaction between Akt and Src, and increases Akt tyrosine phosphorylation After the stimulation of extracellular signaling, PI3K catalyzes the conversion of PIP2 to PIP3, which recruits Akt to the cell membrane. The membrane-bound Akt is fully activated by two phosphorylation events: Thr308 by PDK1 and Ser473 by mTORC2. These sites are independent in sequence, and both are necessary for the full activation of Akt. 17 As shown in Figure 5a , hPEBP4 enhanced Akt phosphorylation at both Ser473 and Thr308, indicating that hPEBP4 may affect the upstream reactions involved in Akt activation. Recent studies have shown that the phosphorylation of Akt at Tyr315/326 by Src is a prerequisite for Thr308 and Ser473 phosphorylation. [18] [19] [20] The tyrosine phosphorylation of Akt was assayed using an IP assay. 18 Src overexpression-induced Akt tyrosine phosphorylation was enhanced when hPEBP4 was overexpressed and impaired after hPEBP4 silencing (Figure 5c ). Another Akt tyrosine kinase, PTK6, 21 was not affected when hPEBP4 was overexpressed or silenced (Supplementary Figure 6A) , Moreover, the co-immunoprecipitation assay in 293T cells showed that hPEBP4 interacted with Src but not with PTK6 (Supplementary Figure 6B) . These results indicate that hPEBP4 specifically promoted the tyrosine phosphorylation of Akt by Src and thereby enhanced Akt activation. Simultaneously, serum stimulation led to a dramatic increase in the tyrosine phosphorylation of Akt in the control cells. Compared with the mock transfectants, the MDA-MB-231/hPEBP4-B transfectants exhibited a higher level of tyrosine phosphorylation of Akt, whereas the silencing of hPEBP4 inhibited the tyrosine phosphorylation of Akt (Figure 5b ). hPEBP4 had no effect on Src activation in MDA-MB-231 cells (Supplementary Figure 6C) , excluding the possibility that hPEBP4 regulates Akt tyrosine phosphorylation by affecting Src activation.
hPEBP4 has been reported to form ternary complexes with Raf-1 and MEK and to scaffold this interaction. hPEBP4 promotes the metastasis of breast cancer H Li et al mechanism might operate in the Akt signaling pathway. Endogenous hPEBP4, Akt and Src were co-purified with each other from MDA-MB-231 cells (Figure 5d ). The association between Src and Akt was increased by serum stimulation, and this association was enhanced by ectopic hPEBP4 expression. In contrast, the Akt and Src interaction was dramatically reduced in hPEBP4-silenced cells compared with control cells (Figure 5e ), strongly suggesting that hPEBP4 is essential for the association of Akt with Src, which is required for Akt tyrosine phosphorylation by Src. The interaction kinetics of the hPEBP4/Akt/Src signaling complex in response to serum stimulation was further investigated in MDA-MB-231 cells. Akt was rapidly recruited to Src after serum treatment (Figures 5e and f) . The amount of hPEBP4 co-immunoprecipitated with Akt was dramatically increased after serum stimulation for 10 min, decreased to undetectable levels after 30 min and then returned to the basal level after 2 h (Figure 5f ). We obtained the same association kinetics between Akt/Src and hPEBP4 when an hPEBP4-specific antibody was used in the immunoprecipitation assay (Figure 5f ). The largest amounts of both Akt and Src co-immunoprecipitated with hPEBP4 occurred after 10 min of serum stimulation. This time-dependent association of hPEBP4 with Akt/Src possibly indicates that the scaffolding function of hPEBP4 and the hPEBP4 interaction in the complex are disrupted by some unknown mechanism to avoid Akt hyperactivation.
Mapping the hPEBP4/Akt and hPEBP4/Src interacting domains Akt has pleckstrin homology (PH), catalytic (CAT) and C-terminal (TAIL) domains. 22 We examined the interaction of these (Figure 6a ). Src has Src homology 2 (SH2), Src homology 3 (SH3) and catalytic (KD) domains. 23, 24 The Src SH3 domain mutant but not the SH2 and KD mutants were immunoprecipitated with hPEBP4 ( Figure 6b ). To identify which regions of hPEBP4 were responsible for its interactions with Akt and Src, we constructed two deletion mutants of hPEBP4, consisting of the PEB domain (amino acids 76-225 of hPEBP4) or the p75 domain (amino acids 1-75 of hPEBP4, which lacks the highly conserved PEB domain). Similar co-immunoprecipitation experiments showed that only the PEB interacted with Akt and Src (Figures 6c and d) . We further tested the effect of hPEBP4 mutants on Akt phosphorylation, cell invasion and the interaction between Akt with Src in MDB-MA-231 cells. Neither p75PEBP4 nor the PEB had any effect on Akt phosphorylation, cell invasion and the interaction between Akt with Src (Figures 6e and f) , indicating that hPEBP4 required not only the PEB domain but also the non-conserved 1-75 amino acid domain to promote the association of Akt with Src, as well as cell invasion. Collectively, the PEB domain of hPEBP4 bound the PH and CAT domains of Akt and the SH3 domain of Src. Those interactions of hPEBP4 with Akt and Src are essential for the enhanced Akt tyrosine phosphorylation by Src and subsequent full activation of Akt, which then contributes to the pro-invasive effect of hPEPB4 of breast cancer cells. hPEBP4 promotes the metastasis of breast cancer H Li et al DISCUSSION hPEBP4 functions as an anti-apoptotic molecule, and its expression is positively correlated with the severity of prostate and breast cancer. [6] [7] [8] In this study, we have identified a novel prometastatic function for hPEBP4. hPEBP4 was highly expressed in metastatic breast cancer tumors and lymph node metastases. This ectopic hPEBP4 expression in the breast cancer cell line MDA-MB-231 promoted cell invasion and hPEBP4 silencing significantly suppressed the cell invasion. We further confirmed the promoting effect of hPEBP4 on spontaneous lung metastasis and lung metastatic seeding in a mouse model. hPEBP4 also potentiated the invasion of colorectal cancer cells, melanoma and liver carcinomas in vitro.
Cancer metastasis is a complicated process regulated by multiple metastatic genes. The overexpression of hPEBP4 promoted Akt activation but inhibited ERK1/2 activation. Accordingly, MDA-MB-231 cells overexpressing hPBEP4 became more metastatic and expressed higher levels of MMPs, effects that could be reversed by PI3K inhibitors. In contrast, the silencing of hPEBP4 decreased Akt activation but increased ERK1/2 activation, resulting in reductions in the invasion ability and MMP expression. Transfection of Myr-Akt restored the impaired invasion ability and MMP expression in the hPEBP4-silenced MDA-MB-231 cells, whereas the MEK inhibitor could not do so, indicating that the hPEBP4-mediated regulation of Akt activation appears to be responsible for the observed enhancement of breast cancer invasion. Significantly increased Akt activation has been detected in metastatic breast cancer. 25, 26 Thus, the abundant expression of hPEBP4 might lead to the higher activation of Akt, resulting in the high expression levels of the MMPs, which contribute to the invasion of breast cancer cells.
Akt is phosphorylated at Thr308 and Ser473 by PDK1 and mTORC2, respectively, resulting in the full activation of Akt kinase. 27, 28 hPEBP4 promoted phosphorylation at both Ser473 and Thr308 sites, indicating that hPEBP4 participated upstream of Akt activation. hPEBP4 did not influence the ubiquitination of Akt, which is required for Akt membrane recruitment and phosphorylation 29 (data not shown). Interestingly, hPEBP4 promoted Src-induced tyrosine phosphorylation of Akt, which is a prerequisite for Akt serine/threonine phosphorylation. [18] [19] [20] However, another tyrosine kinase, PTK6, induced AKT tyrosine phosphorylation that did not differ when hPEBP4 was overexpressed or silenced. In addition, hPEBP4 did not interact with PTK6 (Supplementary Figure 5C) . We also found that hPEBP4 dramatically promoted the association between Akt and Src. The Akt/Src/hPEBP4 complex was observed in the MDA-MB-231 cells, and serum stimulated the formation of the Akt/Src/hPEBP4 complex in vivo by 10 min. Unexpectedly, the association of hPEBP4 with the Akt/Src complex was undetectable after 30 min of serum stimulation and was restored to basal levels at 2 h, suggesting that hPEBP4 may function as a scaffolding molecule and that hPEBP4 interaction in the complex is disrupted by some unknown mechanism to avoid Akt hyperactivation. hPEBP4 has been reported to suppress Src activation and disrupt the interaction between Src and ERa via the association with Src in MCF-7 breast cancer cells, leading to ERa degradation. 30 However, we did not observe any effect of hPEBP4 on Src activation in the ERa-negative MDA-MB-231 cells. hPEBP4 interacted with the PH and CAT domains of Akt via its PEB domain. The PEB domain was also responsible for the interaction with the SH3 domain of Src.
The human tissue microarrays showed hPEBP4 expression was positively correlated with the metastasis of clinical breast cancer. However, hPEBP4 was not specially expressed in metastatic breast tumor tissue, as most of the primary carcinomas expressed hPEBP4. Thus, hPEBP4 could not be a specific marker for the diagnosis of metastatic breast cancer. We also observed that overexpression of hPEBP4 in nonmetastatic breast cancer cell line MCF-7 did not change the invasive ability of MCF-7 cells (data not shown), indicating that hPEBP4 needs the metastatic context to exert its promoting effect on breast cancer invasion. Considering the transition from the primary cancer cells to metastatic cancer cells includes complicated genetic changes, it will be necessary to explore the molecules that cooperated with hPEBP4 to promote tumor metastasis.
As a member of the PEB protein family, hPEBP4 has a PEB domain, as does RKIP (PEBP1). However, these domains appear to have distinct roles in cancer invasion and apoptosis. RKIP/PEBP1 is proapoptotic, [31] [32] [33] whereas hPEBP4 is anti-apoptotic. [6] [7] [8] [9] Recently, RKIP has been implicated as a metastatic suppressor for prostate cancer and breast cancer because its expression is significantly decreased in lymph node metastases compared with the primary breast cancer. [34] [35] [36] Although hPEBP4 interacted with Akt and Src via its PEB domain, PEB had no effect on cell invasion or Akt activation, indicating that the non-conserved domain is essential for the function of hPEBP4 and responsible for the different effects of RKIP and hPEBP4 on invasion and apoptosis. Further investigations will be required to clarify the exact mechanisms responsible for the different functions of hPEBP4 and RKIP/PEBP1.
In summary, we found a novel metastasis-promoting function for hPEBP4. Expression of hPEBP4 was associated with an increased invasive ability of breast cancer cells. We further demonstrated that hPEBP4 functioned as an adapter molecule, promoting the association of Akt with Src, thus enhancing Akt activation via tyrosine phosphorylation, which modulated metastasis-related factors and ultimately facilitated cell invasion. Regardless of the exact mechanism by which hPEBP4 functions, the highly significant upregulation of hPEBP4 expression in breast cancer metastases could provide a new therapeutic target for the treatment of metastatic breast cancer.
MATERIALS AND METHODS

Cell culture
MDA-MB-231-Luc-D3H2LN cells (Xenogen, Hopkinton, MA, USA) were grown in minimum essential medium (MEM) medium with 10% fetal bovine serum (FBS). All the other cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). The stable transfectants overexpressing hPEBP4 were generated by transduction with hPEBP4-B expression vectors or pcDNA3.1/Flag(-)B vectors in MDA-MB-231 cells. For the stable silencing of hPEBP4 expression, MDA-MB-231 cells were transfected with a plasmid expressing a hairpin small interfering RNA against hPEBP4 (shPEBP4) or the shNC plasmid and screened with 500 mg/ml G418 (Merck, Darmstadt, Germany). Individual G418-resistant colonies were named MDA-MB-231/hPEBP4-B or MDA-MB-231/mock and MDA-MB-231/shPEBP4 or MDA-MB-231/shNC. The hPEBP4 expression was confirmed by real-time PCR and western blot analysis.
Reagents and plasmids
MEK inhibitor U0126 and PI-3K inhibitor LY294002 were purchased from Calbiochem (La Jolla, CA, USA). Antibodies for phospho-Akt (Ser473), phospho-ERK1/2, phospho-JNK, phospho-p38, phospho-p65 (NF-kB), phospho-Src (Tyr416), phospho-tyrosine, Akt, ERK1/2, JNK, p38, p65NF-kB, Src and the Akt rabbit mAb (Sepharose bead-conjugated) were from Cell Signaling Technology (Beverly, MA, USA). Antibodies for phospho-Akt (Thr308), E-cadherin, vimentin and b-catenin were from Epitomics (Burlingame, CA, USA). Antibodies for MMP1, MMP2, MMP9 and MMP13 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The PE-conjugated antihuman antibodies for CCR7 and CXCR4 were obtained from BD Biosciences (San Jose, CA, USA). The full-length coding region of hPEBP4 was subcloned into the expression vector pcDNA3.1/Myc-His(-)B and named as hPEBP4-B. Also, p75PEBP4 (amino acids 1-75 of hPEBP4, which lacks the highly conserved PEB domain), the PEB domain (amino acids 76-225 of hPEBP4) and the vector expressing a hairpin small interfering RNA against hPEBP4 (shPEBP4) or Akt1 (shAKT1) were constructed as described previously. 6 The vectors for full-length Src and the Src fragments (HA-Src, Flag-KD, Flag-SH2 and Flag-SH3) and the vectors for Myr-Akt and Akt fragments (GFP-PH, GFP-TAIL and HA-CAT) were generated by PCR amplification.
Immunohistochemical analysis of hPEBP4 expression in breast cancer
The human tissue microarrays of the normal breast and breast cancer tissues were obtained from Alana (Xi'an, China). The arrays contain a total of 128 dots. Each dot represents one normal or cancerous tissue from each individual specimen that was selected and pathologically confirmed. The microarrays were fixed with formalin, embedded in paraffin and immunostained with anti-hPEBP4 (Abcam, Cambridge, MA, USA) using the avidin-biotin peroxidase complex method. The results were scored on the basis of the staining intensity in a blinded fashion, which was graded according to the following criteria: À (no tumor cells stained), ± (weak and partial staining, 10-20% of cells stained), þ (moderate staining, 20-60% of cells stained) and þ þ (strong staining, 460% of cells stained).
In vitro migration and invasion assay
The cells were suspended in serum-free medium, and medium supplemented with 10% serum was used as the chemoattractant in the lower chamber. After 24 h, the cells were removed from the upper filter surfaces, and the cells on the lower surfaces were stained with crystal violet. 37 For the transwell migration assays, 1-2 Â 10 4 cells were cultured in the top chamber containing the non-coated membrane (Costar, Cambridge, MA, USA). For the invasion assays, 5-8 Â 10 4 cells were placed in the top chamber that contained a Matrigel-coated membrane (BD Biosciences, Franklin Lakes, NJ, USA).
Gelatin zymography
The gelatin zymography was used to determine the activity of MMP2 and MMP9 in the conditioned medium. The medium was collected and the cells were removed by centrifugation. Then, 2 mg of protein from the concentrated cell-conditioned medium was loaded onto a 10% SDSpolyacrylamide gel polymerized with 5 mg/ml gelatin (Sigma, St Louis, MO, USA). After electrophoresis, the gels were renatured by soaking for 30 min at room temperature in 2.5% Triton X-100. The gels were then incubated in a developing buffer (50 mM Tris-HCl buffer (pH 7.4), 10 mM CaCl 2 ) overnight at 37 1C. The gels were stained with 0.5% Coomassie brilliant blue R-250 and destained in the washing solution without dye. The transparent bands of gelatinolytic activity were visualized as clear bands against the blue-stained gelatin background. 38 Lentiviral production and infection Lentiviral production was performed using the Lenti-X Lentiviral Expression System (Clontech, Mountain View, CA, USA), according to the manufacturer's instructions. In brief, recombinant lentiviruses were constructed by inserting hPEBP4 into the Lenti-X plasmid vector. The recombinant Lenti-X plasmid vectors and Lenti-X HTX packaging mix were co-transfected into 293FT cells. After 48 h, the viral supernatants were collected, filtered and concentrated, and the virus was quantified according to the manufacturer's instructions. The Lenti-X shRNA Expression System (Clontech) was hPEBP4 promotes the metastasis of breast cancer H Li et al used to obtain the shPEBP4 lentivirus. The concentrated virus was used to infect 6 Â 10 5 cells in a 60 mm dish with 10 mg/ml polybrene (Sigma).
In vivo metastasis
The MDA-MB-231 cells that had been engineered to stably express firefly luciferase (MDA-MB-231-Luc-D3H2LN) were infected with lentiviruses carrying hPEBP4 cDNA or shPEBP4. These cells were inoculated into the left abdominal mammary fat pad (3 Â 10 6 cells) or injected into the lateral tail vein (1-3 Â 10 6 cells) of 6-week-old female nude mice. Subcutaneous tumors were measured with a dial-caliper once a week, and the volumes were determined using the following formula: width 2 Â length Â 0.52. Each volume value represents the mean±s.e. Tumor metastasis was measured by quantitative bioluminescence imaging after 8 weeks for the orthotopic implantation groups and at 6 weeks for the intravenous injection groups. For the bioluminescence imaging, the mice were anesthetized and given 150 mg/g D-luciferin in PBS by intraperitoneal injection. Fifteen minutes after the injection, the bioluminescence was imaged with a chargecoupled device camera (IVIS; Xenogen). In the intravasation assays, the isolated RNA from mouse blood was analyzed for human GAPDH and mouse GAPDH by qRT-PCR. 35, 39 Statistical analysis
The statistical analysis was performed using Student's t-test to identify significant differences unless otherwise indicated. Differences were considered significant at a P-value of o0.05.
